News >

Optimizing Combinations Next Challenge in mRCC

Brandon Scalea
Published: Thursday, Dec 20, 2018

Bradley G. Somer, MD

Bradley G. Somer, MD

As the treatment paradigm for metastatic renal cell carcinoma (mRCC) continues to evolve, combination therapy is likely to be an important part of the future, said Bradley G. Somer, MD.

For example, in the phase III CheckMate-214 trial, which served as the basis for the nivolumab/ipilimumab FDA approval, overall survival (OS) and response rates were significantly higher with the combination compared with the frontline standard sunitinib (Sutent) in patients with previously untreated RCC.1

With both immunotherapy and TKIs available as single agents in this space, there have been studies exploring the 2 mechanisms of action in combination.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication